Simpson Thacher is representing PHC Holdings Corporation (formerly known as Panasonic Healthcare Holdings Co., Ltd.) in connection with its definitive agreement to acquire the Anatomical Pathology business of Thermo Fisher Scientific Inc. (NYSE: TMO) for approximately US$1.14 billion. The transaction, which is expected to close in the second quarter of 2019, is subject to customary closing conditions and the receipt of applicable regulatory approvals.
Thermo Fisher’s Anatomical Pathology business is one of the leading providers of microscope slides, instruments and consumables in the industry and is part of Thermo Fisher’s Specialty Diagnostics Segment, operating in the U.S., Europe and China. PHCHD is a global healthcare company that offers value-added products and services across diabetes care, diagnostics, life sciences and healthcare IT.
The Simpson Thacher team includes Katie Sudol and Johanna Mayer (M&A); Makiko Harunari, Shahpur Kabraji, Atsushi Usui and Tomohiro Koyasu (Banking and Credit); Joseph Tootle and Dmitry Zelik (Tax); Tristan Brown, Alyssa Ohanian and Erik Ward (Executive Compensation and Employee Benefits); Lori Lesser and Alysha Sekhon (Intellectual Property); Adeeb Fadil and Noreen Lavan (Environmental); David Vann, Noritaka Kumamoto, Etienne Renaudeau and Megan Griffith (Antitrust); Krista McManus and Dennis Loiacono (Real Estate); and Steve DeLott (Insurance). Janet Kyung-Ah Yu also provided valuable assistance.